Conventional amphotericin B elicits markers of immunogenic cell death on leukemic blasts, mediates immunostimulatory effects on phagocytic cells, and synergizes with PD-L1 blockade

Conventional amphotericin B elicits markers of immunogenic cell death on leukemic blasts, mediates immunostimulatory effects on phagocytic cells, and synergizes with PD-L1 blockade

Immunostimulatory regimens are a game changer in the fight against cancer, but still only a minority of patients achieve clinical benefit. Combination with immunomodulatory drugs and agents converting otherwise non-immunogenic forms of cell death into bona fide “immunogenic cell death” (ICD) could i...

Full description

Bibliographic Details
Main Authors: G. Kofla, C. Radecke, M. Frentsch, W. Walther, S. Stintzing, H. Riess, L. Bullinger, I-K. Na
Format: Article
Language:English
Published: Taylor & Francis Group 2022-12-01
Series:OncoImmunology
Subjects:
Amphotericin B
ICD
calreticulin
PD-L1
immunomodulatory therapy
Online Access:https://www.tandfonline.com/doi/10.1080/2162402X.2022.2068109

Internet

https://www.tandfonline.com/doi/10.1080/2162402X.2022.2068109

Similar Items